Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TROV
Previous Symbol
CUSIPN/A
Phone858-952-7570
Debt
Debt-to-Equity RatioN/A
Current Ratio6.03
Quick Ratio6.03
Price-To-Earnings
Trailing P/E Ratio-0.11
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$500,000.00
Price / Sales31.73
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.48 per share
Price / Book0.47
Profitability
EPS (Most Recent Fiscal Year)($6.48)
Net Income$-24,900,000.00
Net Margins-3,066.39%
Return on Equity-139.55%
Return on Assets-95.36%
Miscellaneous
Employees17
Outstanding Shares22,990,000
Market Cap$16.09 million
OptionableOptionable
TrovaGene (NASDAQ:TROV) Frequently Asked Questions
What is TrovaGene's stock symbol?
TrovaGene trades on the NASDAQ under the ticker symbol "TROV."
When did TrovaGene's stock split? How did TrovaGene's stock split work?
Shares of TrovaGene reverse split before market open on Monday, June 4th 2018. The 1-12 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 1st 2018. An investor that had 100 shares of TrovaGene stock prior to the reverse split would have 8 shares after the split.
How were TrovaGene's earnings last quarter?
TrovaGene Inc (NASDAQ:TROV) announced its quarterly earnings results on Wednesday, November, 7th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.33) by $0.15. The medical research company had revenue of $0.09 million for the quarter. TrovaGene had a negative return on equity of 139.55% and a negative net margin of 3,066.39%. View TrovaGene's Earnings History.
When is TrovaGene's next earnings date?
What price target have analysts set for TROV?
2 equities research analysts have issued twelve-month price objectives for TrovaGene's shares. Their predictions range from $7.00 to $7.00. On average, they anticipate TrovaGene's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 914.5% from the stock's current price. View Analyst Price Targets for TrovaGene.
What is the consensus analysts' recommendation for TrovaGene?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TrovaGene in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TrovaGene.
What are Wall Street analysts saying about TrovaGene stock?
Here are some recent quotes from research analysts about TrovaGene stock:
- 1. According to Zacks Investment Research, "Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. " (9/29/2018)
- 2. Maxim Group analysts commented, "Trovagene reported 2Q18 with a net loss of $6.5M and ended the period with $18.5M in cash on the balance sheet. With operating expenses of $4.5M, which we estimate should rise as clinical programs around PCM-075 advance, Trovagene has runway into mid-2019." (8/6/2018)
Has TrovaGene been receiving favorable news coverage?
News articles about TROV stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TrovaGene earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of TrovaGene's key competitors?
Some companies that are related to TrovaGene include Brainstorm Cell Therapeutics (BCLI), Entera Bio (ENTX), Genocea Biosciences (GNCA), Arsanis (ASNS), Oncobiologics (ONS), BIONDVAX PHARMA/S (BVXV), AVITA MED LTD/S (AVMXY), TRACON Pharmaceuticals (TCON), Proteon Therapeutics (PRTO), Vical (VICL), Curis (CRIS), Titan Pharmaceuticals (TTNP), Vaxart (VXRT), CytRx (CYTR) and Mymetics (MYMX).
Who are TrovaGene's key executives?
TrovaGene's management team includes the folowing people:
- Dr. Thomas H. Adams, Interim CEO & Chairman of the Borad (Age 75)
- Dr. Mark Erlander, Chief Scientific Officer (Age 58)
- Ms. Elizabeth Anderson CPA, VP of Fin. and Admin.
- Mr. George Samuel J.D., VP & Gen. Counsel
- Ms. Vicki Kelemen, Sr. Director of Communications
Who are TrovaGene's major shareholders?
TrovaGene's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.60%), Vanguard Group Inc. (1.04%) and Virtu Financial LLC (0.78%). Company insiders that own TrovaGene stock include Mark Erlander, Rodney S Markin, Stanley Tennant and William J Welch. View Institutional Ownership Trends for TrovaGene.
Which major investors are buying TrovaGene stock?
TROV stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc. and Virtu Financial LLC. Company insiders that have bought TrovaGene stock in the last two years include Mark Erlander, Rodney S Markin, Stanley Tennant and William J Welch. View Insider Buying and Selling for TrovaGene.
How do I buy shares of TrovaGene?
Shares of TROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TrovaGene's stock price today?
One share of TROV stock can currently be purchased for approximately $0.69.
How big of a company is TrovaGene?
TrovaGene has a market capitalization of $16.09 million and generates $500,000.00 in revenue each year. The medical research company earns $-24,900,000.00 in net income (profit) each year or ($6.48) on an earnings per share basis. TrovaGene employs 17 workers across the globe.
What is TrovaGene's official website?
How can I contact TrovaGene?
TrovaGene's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-952-7570 or via email at [email protected]
MarketBeat Community Rating for TrovaGene (NASDAQ TROV)
MarketBeat's community ratings are surveys of what our community members think about TrovaGene and other stocks. Vote "Outperform" if you believe TROV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TROV will underperform the S&P 500 over the long term. You may vote once every thirty days.
